Edwards Lifesciences Corp (EW) stock
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3058% above fair value
$105.80−0.01 (-0.01%)
Close on Nov 12, 2026Market cap $60.98BP/E 59.8Yield –
Edwards Lifesciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Edwards Lifesciences's total debt was $598.80M at Sep 30, 2026. For fiscal 2025 it was $598.30M, up 0.1% from the year before. Over ten years it grew 0.0% a year on average. The highest annual figure on record is $1.04B in fiscal 2017.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $598.30M | +0.1% |
| FY2024 | Dec 31, 2024 | $597.70M | +0.1% |
| FY2023 | Dec 31, 2023 | $597.00M | +0.1% |
| FY2022 | Dec 31, 2022 | $596.30M | +0.1% |
| FY2021 | Dec 31, 2021 | $595.70M | +0.1% |
| FY2020 | Dec 31, 2020 | $595.00M | +0.1% |
| FY2019 | Dec 31, 2019 | $594.40M | +0.1% |
| FY2018 | Dec 31, 2018 | $593.80M | -42.7% |
| FY2017 | Dec 31, 2017 | $1.04B | +26.0% |
| FY2016 | Dec 31, 2016 | $822.30M | +37.8% |
| FY2015 | Dec 31, 2015 | $596.90M | -0.2% |
| FY2014 | Dec 31, 2014 | $598.10M | +0.8% |
| FY2013 | Dec 31, 2013 | $593.10M | +213.3% |
| FY2012 | Dec 31, 2012 | $189.30M | +109.6% |
| FY2009 | Dec 31, 2009 | $90.30M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $598.80M | +0.1% |
| Q2 FY2026 | Jun 30, 2026 | $598.70M | +0.1% |
| Q1 FY2026 | Mar 31, 2026 | $598.50M | +0.1% |
| Q4 FY2025 | Dec 31, 2025 | $598.30M | +0.1% |
| Q3 FY2025 | Sep 30, 2025 | $598.20M | +0.1% |
| Q2 FY2025 | Jun 30, 2025 | $598.00M | +0.1% |
| Q1 FY2025 | Mar 31, 2025 | $597.80M | +0.1% |
| Q4 FY2024 | Dec 31, 2024 | $597.70M | +0.1% |
| Q3 FY2024 | Sep 30, 2024 | $597.50M | +0.1% |
| Q2 FY2024 | Jun 30, 2024 | $597.30M | +0.1% |
| Q1 FY2024 | Mar 31, 2024 | $597.20M | +0.1% |
| Q4 FY2023 | Dec 31, 2023 | $597.00M | +0.1% |
| Q3 FY2023 | Sep 30, 2023 | $596.80M | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | $596.70M | +0.1% |
| Q1 FY2023 | Mar 31, 2023 | $596.50M | +0.1% |
| Q4 FY2022 | Dec 31, 2022 | $596.30M | +0.1% |
| Q3 FY2022 | Sep 30, 2022 | $596.20M | +0.1% |
| Q2 FY2022 | Jun 30, 2022 | $596.00M | +0.1% |
| Q1 FY2022 | Mar 31, 2022 | $595.90M | +0.1% |
| Q4 FY2021 | Dec 31, 2021 | $595.70M | +0.1% |
| Q3 FY2021 | Sep 30, 2021 | $595.50M | +0.1% |
| Q2 FY2021 | Jun 30, 2021 | $595.40M | +0.1% |
| Q1 FY2021 | Mar 31, 2021 | $595.20M | +0.1% |
| Q4 FY2020 | Dec 31, 2020 | $595.00M | +0.1% |
| Q3 FY2020 | Sep 30, 2020 | $594.90M | +0.1% |
| Q2 FY2020 | Jun 30, 2020 | $594.70M | +0.1% |
| Q1 FY2020 | Mar 31, 2020 | $594.60M | +0.1% |
| Q4 FY2019 | Dec 31, 2019 | $594.40M | +0.1% |
| Q3 FY2019 | Sep 30, 2019 | $594.20M | -50.2% |
| Q2 FY2019 | Jun 30, 2019 | $594.10M | -50.2% |
| Q1 FY2019 | Mar 31, 2019 | $593.90M | -43.7% |
| Q4 FY2018 | Dec 31, 2018 | $593.80M | -42.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.19B | +15.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.19B | +17.3% |
| Q1 FY2018 | Mar 31, 2018 | $1.05B | +24.4% |
| Q4 FY2017 | Dec 31, 2017 | $1.04B | +26.0% |
| Q3 FY2017 | Sep 30, 2017 | $1.03B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.02B | – |
| Q1 FY2017 | Mar 31, 2017 | $847.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $822.30M | – |
See a number that looks wrong?